Micafungin Shortage: What Providers and Prescribers Need to Know in 2026

Micafungin (Mycamine) remains a cornerstone of therapy for candidemia, invasive candidiasis, esophageal candidiasis, and prophylaxis in hematopoietic stem cell transplant (HSCT) recipients. For infectious disease physicians, hospitalists, transplant specialists, and clinical pharmacists, understanding the current supply landscape for micafungin is essential for proactive patient management. This clinical briefing covers the 2026 supply status, shortage risk factors, alternative protocols, and practical guidance for maintaining uninterrupted antifungal therapy.

Current Supply Status (2026)

As of early 2026, micafungin is not listed on the FDA Drug Shortage Database. The market is supplied by multiple generic manufacturers following patent expiration, and HCPCS J2248 (injection, micafungin sodium, 1 mg) is reimbursed at approximately $0.315 per mg by private payers as of Q4 2025. Between 2022 and 2024, the average selling price dropped by over 15%, reflecting competitive generic market dynamics. Most hospital formularies maintain adequate stock; however, specialty and home infusion pharmacies can experience localized back orders, particularly during periods of increased demand.

Shortage Vulnerability: Why Micafungin Is at Risk

Micafungin shares the risk factors common to all sterile injectable specialty medications:

Complex sterile manufacturing: Lyophilized powder for injection requires specialized aseptic manufacturing facilities. GMP deficiencies identified during FDA inspections can result in production halts.

Global raw material dependence: Active pharmaceutical ingredients for many sterile injectables are sourced from India and China. Supply chain disruptions in these regions can affect production timelines.

Thin profit margins: Declining reimbursement from competitive generic pricing reduces the financial incentive for manufacturers to invest in redundant production capacity or buffer inventory.

Demand growth: Rising rates of invasive fungal infections driven by increasing immunocompromised patient populations (transplant, oncology, HIV) create sustained upward pressure on demand.

Clinical Alternatives: Evidence-Based Protocols

Per 2016 IDSA guidelines (the most recent comprehensive Candida treatment guidelines), all three FDA-approved echinocandins (micafungin, caspofungin, anidulafungin) are classified as equivalent first-line therapy for candidemia and most forms of invasive candidiasis. This means intra-class switching is typically clinically appropriate, facilitating formulary substitution during shortage conditions. Providers should be aware of the following alternative protocols:

Caspofungin (Cancidas / Generic)

Standard adult dosing: 70 mg IV loading dose on day 1, then 50 mg IV once daily. Dose adjustment to 70 mg/day in patients with moderate hepatic impairment (Child-Pugh 7-9). Caspofungin has demonstrated non-inferiority to amphotericin B for empiric febrile neutropenia and is the only echinocandin with this indication. Available as a widely stocked generic.

Anidulafungin (Eraxis / Generic)

Standard adult dosing: 200 mg IV loading dose on day 1, then 100 mg IV once daily for candidemia and invasive candidiasis; 100 mg loading, then 50 mg daily for esophageal candidiasis. No dose adjustment required for hepatic or renal impairment. Anidulafungin undergoes non-enzymatic degradation and has the fewest drug-drug interactions of the echinocandins, making it an attractive choice in transplant patients on complex immunosuppression regimens.

Rezafungin (Rezzayo)

FDA-approved in 2023 for adults with candidemia and invasive candidiasis. Dosing: 400 mg IV on week 1, then 200 mg IV weekly. Rezafungin's weekly dosing schedule reduces infusion burden and is particularly advantageous for outpatient or home infusion continuation of therapy. Not yet approved for esophageal candidiasis or HSCT prophylaxis. Availability may be limited in some formularies; verify with pharmacy before prescribing.

Step-Down to Azoles: When Is It Appropriate?

Per IDSA guidelines, step-down to fluconazole (400 mg/day) is appropriate in stable patients with candidemia after 5 to 7 days of echinocandin therapy, provided: (1) the patient is clinically stable and blood cultures have cleared; (2) the causative Candida species is confirmed susceptible to fluconazole; and (3) no evidence of metastatic infection that may benefit from continued echinocandin coverage. Fluconazole is not appropriate for C. krusei or fluconazole-resistant C. glabrata strains. For esophageal candidiasis, transition to oral fluconazole is standard practice after initial IV therapy.

Home Infusion Transition: Avoiding Access Gaps

The most common access disruption point for micafungin is the hospital-to-home transition. Specialty and home infusion pharmacies do not universally stock micafungin, and lead times of 2 to 5 business days are common. Best practices for minimizing discharge-related treatment gaps:

Initiate home infusion coordination 48 to 72 hours before anticipated discharge

Confirm specific micafungin NDC stock (not just the drug name) with the home infusion pharmacy

Provide a bridge supply of 2 to 3 days of medication from the inpatient pharmacy when possible

Consider switching to rezafungin for patients with stable infections who would benefit from weekly rather than daily infusions in the outpatient setting

Drug Interactions to Monitor During Echinocandin Therapy

Micafungin inhibits CYP3A4 weakly and can increase exposure to sirolimus (AUC increased 21%), nifedipine (AUC increased 18%, Cmax increased 42%), and itraconazole (AUC increased 22%). Monitor these agents closely and reduce doses if toxicity occurs. Micafungin does not significantly affect cyclosporine, tacrolimus, or mycophenolate mofetil pharmacokinetics. Caspofungin's interaction profile differs, particularly with rifampin, phenytoin, and cyclosporine, requiring closer monitoring. Anidulafungin has the fewest interactions among echinocandins.

How medfinder Can Help Your Patients

When patients face access barriers, medfinder for providers helps identify pharmacies with micafungin in stock in the patient's area. This can be especially useful during home infusion transitions or when a patient's current pharmacy cannot source the medication. medfinder contacts pharmacies directly and texts results to patients.

For a detailed provider workflow, see our guide: How to help your patients find micafungin in stock.